期刊文献+

布-加综合征患者血清CA125、CA19-9的临床意义 被引量:2

The clinical significance of the determination of serum CA19-9 and CA125 levels in patients with Budd-Chiari syndrome
暂未订购
导出
摘要 目的探讨布-加综合征患者血清中CA125、CA19-9变化的临床意义。方法回顾分析2011年2月-2012年1月收治的188例布-加综合征患者血清CA125、CA19-9水平,分析布-加综合征不同亚型之间的差异,并与肝硬化患者和正常体检人群(对照组)血清CA125、CA19-9水平比较。试用ROC分析评价CA19-9、CA125对布-加综合征、肝硬化的诊断价值。结果布-加综合征组、肝硬化组血清CA125、CA19-9水平较高,与对照组比较差异均有统计学意义(P<0.05);布-加综合征组与肝硬化组血清CA19-9比较差异有统计学意义(P<0.01);但两组间血清CA125比较差异无统计学意义(P>0.05)。布-加综合征各分型间的CA125、CA19-9比较差异无统计学意义(P>0.05)。血清CA19-9用于诊断布-加综合征的最佳临界值为31.14 u/ml,灵敏度为64%,特异度为85.5%。结论血清CA125和CA19-9在评价布-加综合征患者肝损害程度、判断疾病发展有一定的临床意义。 Objective To discuss the clinical significance of the determination of serum CA19-9 and CA125 levels in patients with Budd-Chiari syndrome (BCS). Methods During the period from Feb. 2011 to Jan. 2012, a total of 188 patients with BCS were admitted to authors' hospital. The recorded serum CA125 and CA19-9 levels were retrospectively analyzed. The differences in serum CA125 and CA19- 9 levels of different BCS types were analyzed. The serum CA125 and CA19-9 levels of BCS patients (BCS group) were compared with those of cirrhosis patients(cirrhosis group) as well as healthy subjects(control group). By using ROC analysis the value of CA125 and CA19-9 levels in diagnosing BCS and cirrhosis was assessed. Results Statistically significant difference in CA125 and CA19-9 levels existed between BCS group and control group as well as between cirrhosis group and control group (P 〈 0.05). The difference in CA19-9 levels between BCS group and cirrhosis group was also statistically significant (P 〈 0.01), although the difference in CA125 levels between BCS group and cirrhosis group was not significant (P 〉 0.05). The differences in CA125 and CA19-9 levels among different BCS types were not significant (P 〉 0.05). The optimal marginal value of CA19-9 level in diagnosing BCS was 31.14U/ml, and the sensitivity and specificity were 64% and 85.5%, respectively. Conclusion The determination of CA125 and CA19- 9 levels has certain clinical value in assessing the severity of hepatic injury as well as in judging the progress of BCS. (J Intervent Radiol, 2012,21: 728-731)
出处 《介入放射学杂志》 CSCD 北大核心 2012年第9期728-730,共3页 Journal of Interventional Radiology
基金 国家自然科学基金资助项目(81141074)
关键词 布-加综合征 肝硬化 CA125 CA19-9 Budd Chiari syndrome cirrhosis CA125 CA19-9
  • 相关文献

参考文献8

二级参考文献93

共引文献140

同被引文献40

  • 1冷爱民,张桂英.CA125在肝硬化患者中的前瞻性观察[J].世界华人消化杂志,2004,12(7):1759-1760. 被引量:14
  • 2李春艳,刘丽娜,孟华,从令波,宋波.良性腹水患者血清CA125检测的临床意义探讨[J].临床肝胆病杂志,2005,21(4):231-232. 被引量:19
  • 3周永列,邵浙新,高伟,应奇峰,陈永健,皇甫梅生.用积分法评价6项血清肿瘤标志物对原发性肝癌的诊断价值[J].中国实验诊断学,2006,10(3):231-234. 被引量:7
  • 4Liang X,Bi S, Yang W, et al. Epidemiological serosurvey of hepatitisB in China - declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009,27(47):6550-6557.
  • 5Runyon BA, AASLD Practice Guidelines Committee. Management of a-dult patients with ascites due to cirrhosis : update [ J]. Hepatology,2009,49(6):2087 -2107.
  • 6Kamath PS,Wiesner RH,Mainchoc M,et al. A model to predict sur-vival in patients with end stage liver disease[ J]. Hepatology, 2001,33(2):464-470.
  • 7Ashraf MK, Ferdous A, Hossein P, et al. The role of mutations in coreprotein of hepatitis B virus in liver fibrosis[ J]. Virol J, 2009 ,6(1):209 -218.
  • 8Kabawat SE, Bast RC, Bhan AK, et al. Tissue distrihution of a coelomic-epithelium-related antigen recognized by the monoelonal antibody OC125[J]. Int J Gynecol Pathol, 1983, 2(3) : 275-285.
  • 9Cheng D, Xu H, Lu ZJ, et al. Clinical features and etiology of Budd-Chiari syndrome in Chinese patients: a single-center study [J]. J Gastroenterol Hepatol, 2013, 28(6) : 1061-1067.
  • 10Zhang D, Yu M, Xu T, et al. Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population [ J ]. Hepatogastroenterology,2013, 60 (126) : 1297-1301.

引证文献2

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部